July 10, 2025
In this Lifespan interview, we speak with Gabriel Cian, founder of the 2060 Longevity Forum, about how his background in software shaped his views on healthspan innovation, the forum’s approach to scientific and investment credibility, and what he sees as the biggest bottlenecks and opportunities facing the field of longevity today. Hi, Gabriel. Let’s start...
July 07, 2025
The longevity field hasn’t been very good at naming things, but one notable exception is “inflammaging”: the low-grade chronic inflammation that correlates with aging. Recognition has been growing that inflammation, the ubiquitous reaction of the immune system to various stressors, is a major driver of many age-related diseases and possibly one of the limiting factors...
June 09, 2025
In this interview, Boyang Wang of Immortal Dragons discusses the kinds of projects he wants to fund, ways in which the industry can be encouraged to develop, relationships between the East and West in longevity research and development, and what got him involved in longevity. Hello, and welcome to this Lifespan interview, where today, I...
June 05, 2025
On its website, Rejuve.AI, a company co-founded by its dynamic CEO, Jasmine Smith, and a renowned AI researcher, Ben Goertzel, promises a lot of things: to “democratize longevity, globally,” to enable you to “take control of your data, and harness its earning potential,” and to “unite against aging.” We have been following the company for...
May 08, 2025
Michael Levin, professor at Tufts University and director of Allen Discovery Center, has been working for years on how bioelectrical patterns affect development and aging. His research proves that this often-overlooked part of biology is immensely important and that mastering its mechanisms might one day do wonders for human health and longevity. By manipulating ion...
March 24, 2025
Like many people, I’m both wary of and intrigued by people who make bombastic claims. Years in the longevity field have taught me caution but also that big claims are not necessarily outlandish, and few people make bigger claims than Joshua “Scotch” McClure, founder and CEO of Maxwell Biosciences. The company developed Claromers™, synthetic small...